Search research articles
Contact Us
Filters
Showing results (41-50 of 195) with videos related to
Page
of 20
Sort By:
The European Respiratory Journal
|
June 13, 2020
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Jason Weatherald, Louise Bondeelle, Marie-Camille Chaumais, et al.
European Journal of Haematology
|
February 14, 2004
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice
Philippe Rousselot, Jérôme Larghero, Sylvaine Labaume, et al.
Hematology (Amsterdam, Netherlands)
|
May 27, 2022
AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome
Nada Assaf, Christine Lefebvre, Victoria Raggueneau, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
October 27, 2009
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS
Olivia Roth, Odile Spreux-Varoquaux, Stephane Bouchet, et al.
American Journal of Hematology
|
November 11, 2011
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association
Hassan Farhat, Oumedaly Reman, Emmanuel Raffoux, et al.
Journal of Clinical Microbiology
|
February 4, 2006
Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders
Alban Aubry, Raphael Porcher, Julie Bottero, et al.
The FEBS Journal
|
September 26, 2024
The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia
Jaja Zhu, Hippolyte Guérineau, Anne-Margaux Lefebvre-Fortané, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 15, 2013
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
Hagop M Kantarjian, Mikkael A Sekeres, Vincent Ribrag, et al.
Cancer
|
October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia
Hyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
Frontiers in Immunology
|
December 2, 2024
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy
Amandine Decroos, Sarah Meddour, Marine Demoy, et al.
Page
of 20
Search research articles
Search
Showing results (41-50 of 195) with videos related to
Sort By:
Page
of 20
The European Respiratory Journal
|
June 13, 2020
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors
Jason Weatherald, Louise Bondeelle, Marie-Camille Chaumais, et al.
European Journal of Haematology
|
February 14, 2004
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice
Philippe Rousselot, Jérôme Larghero, Sylvaine Labaume, et al.
Hematology (Amsterdam, Netherlands)
|
May 27, 2022
AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome
Nada Assaf, Christine Lefebvre, Victoria Raggueneau, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
October 27, 2009
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS
Olivia Roth, Odile Spreux-Varoquaux, Stephane Bouchet, et al.
American Journal of Hematology
|
November 11, 2011
Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: a phase 1/2 study of the acute leukemia French association
Hassan Farhat, Oumedaly Reman, Emmanuel Raffoux, et al.
Journal of Clinical Microbiology
|
February 4, 2006
Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders
Alban Aubry, Raphael Porcher, Julie Bottero, et al.
The FEBS Journal
|
September 26, 2024
The AXL inhibitor bemcentinib overcomes microenvironment-mediated resistance to pioglitazone in acute myeloid leukemia
Jaja Zhu, Hippolyte Guérineau, Anne-Margaux Lefebvre-Fortané, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 15, 2013
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
Hagop M Kantarjian, Mikkael A Sekeres, Vincent Ribrag, et al.
Cancer
|
October 10, 2013
Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia
Hyacinthe Johnson-Ansah, Joelle Guilhot, Philippe Rousselot, et al.
Frontiers in Immunology
|
December 2, 2024
The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy
Amandine Decroos, Sarah Meddour, Marine Demoy, et al.
Page
of 20